KDR and breast angiosarcoma: An in vitro study demonstrated that 10% of patients with primary and secondary breast angiosarcomas exhibit activating KDR gene mutations [26]; based on their activity in vitro, VEGFR inhibitors could be studied in KDR-overexpressing radiation-associated breast angiosarcomas [27].